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Abstract
Head and neck cancer is treated mainly by surgery and radiotherapy. Normal tissue toxicity due to x-ray exposure
is a limiting factor for treatment success. Many efforts have been employed to develop predictive tests applied to
clinical practice. Determination of lymphocyte radio-sensitivity by radio-induced apoptosis arises as a possible
method to predict tissue toxicity due to radiotherapy. The aim of the present study was to analyze radio-induced
apoptosis of peripheral blood lymphocytes in head and neck cancer patients and to explore their role in predicting
radiation induced toxicity. Seventy nine consecutive patients suffering from head and neck cancer, diagnosed and
treated in our institution, were included in the study. Toxicity was evaluated using the Radiation Therapy Oncology
Group scale. Peripheral blood lymphocytes were isolated and irradiated at 0, 1, 2 and 8 Gy during 24 hours. Apop-
tosis was measured by flow cytometry using annexin V/propidium iodide. Lymphocytes were marked with CD45
APC-conjugated monoclonal antibody. Radiation-induced apoptosis increased in order to radiation dose and fitted
to a semi logarithmic model defined by two constants: a and b. a, as the origin of the curve in the Y axis deter-
mining the percentage of spontaneous cell death, and b, as the slope of the curve determining the percentage of
cell death induced at a determined radiation dose, were obtained. b value was statistically associated to normal tis-
sue toxicity in terms of severe xerostomia, as higher levels of apoptosis were observed in patients with low toxicity
(p = 0.035; Exp(B) 0.224, I.C.95% (0.060-0.904)). These data agree with our previous results and suggest that it is
possible to estimate the radiosensitivity of peripheral blood lymphocytes from patients determining the radiation
induced apoptosis with annexin V/propidium iodide staining. b values observed define an individual radiosensitivity
profile that could predict late toxicity due to radiotherapy in locally advanced head and neck cancer patients. Any-
how, prospective studies with different cancer types and higher number of patients are needed to validate these
results.
Findings
Interpatient heterogeneity in normal tissue reactions due
to different treatments varies considerably [1]. Patients
treated with radiotherapy (RT) will develop clinical toxi-
city and this may limit the success of the treatment [2].
The genetic and molecular mechanisms of therapeutic
radiation sensitivity are still poorly understood [3,4].
The treatment of head and neck cancer includes surgery
and, in advanced stages, radiation. Normal tissue toxicity
induced by RT is the main limiting factor in the treat-
ment progress. Knowledge of individual variations
determining tolerance would be of great value. The abil-
ity of cells to detect and repair DNA damages will con-
dition the intrinsic radiosensitivity [5]. The majority of
radiosensitivity predictive factors are related to gene
expression profiles [6,7], although other approaches
have been recently proposed [8]. Flow cytometry evalua-
tion of lymphocyte apoptosis has been established as a
reliable method to measure radiation-induced damage
[9]. Quantification of radiation-induced apoptosis (RIA)
in peripheral blood lymphocytes (PBLs) has been pro-
posed for the prediction of normal tissue responses after
RT [10,11]. It has been published that radiation-induced
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any medium, provided the original work is properly cited.differences in late toxicity between individuals [12]. A
correlation existed between low levels of RIA in lym-
phocytes and increased late toxicity after radiation ther-
apy. Development of predictive assays for clinical
implementation requires that the test employed displays
both high reproducibility and low variation [13]. Intrin-
sic radiosensitivity is genetically determined and varies
in dependence of the patient and the tumour type. The
aim of the present study was to analyze radio-induced
apoptosis of peripheral blood lymphocytes in head and
neck cancer patients and explore their role in predicting
radiation induced toxicity.
Methods
Seventy nine consecutive patients with histological con-
firmed cell carcinoma of head and neck, diagnosed and
treated in our institution and given inform consent,
were included in the study. Apoptosis analyses were per-
formed between November 2004 and July 2006. The
study was approved by the Research and Ethics Com-
mittee of our institution. Mean age of patients was
55.81 ± 12.02 years (range 19-79, median 58). Clinic-
pathological characteristics of patients are detailed in
Table 1. Evaluation of clinical toxicity was made accord-
ing to the Radiation Therapy Oncology Group (RTOG)
acute and late morbidity scoring system that classifies
toxicity of patients into different levels: grade 1 (mild)
to 4 (severe). Clinical toxicity of patients was evaluated
in each visit. The time point used corresponds to the
last evaluation (Table 2). The mean follow-up was 37.02
± 30.15 months (range 3-148, median 31). Treatment
protocols varied in order to the stage of the disease and
the general state of the patient (Table 1). Patients who
were treated with conventional RT received 1.8-2 Gy
per day to a total mean dose of 69.1 Gy (range 64.8-
72.2). Patients who were treated with high-dose hyper-
fractionated RT received two daily fractions of 1.2 Gy
separated by at least 6 hours to a total mean dose of
78.6 Gy (range 70.0-81.6). PBLs were isolated during fol-
low-up from 10 ml of blood by density gradient centri-
fugation on Ficoll-Hypaque (Lymphoprep, Gybco) as
previously reported [11]. The final concentration of cells
was adjusted to 2 × 10
5 cells/ml in complete RPMI, and
they were separated into four 25-cm
2 flasks. Cells were
irradiated at room temperature with 1, 2 and 8 Gy, 6
mV × rays (Mevatron, Siemens, Germany) at a dose rate
of 50 cGy/min. After irradiation, the preparations were
i n c u b a t e da t3 7 ° Ci n5 %C O 2 during 24 hours. Post
incubation, four samples of 1.5 × 10
5 cells from each
flask (one negative control and three samples for tripli-
cate study) were washed, centrifuged and incubated with
5 μl of monoclonal antibody CD45 APC-conjugated
monoclonal antibody, permitting the exclusion of ery-
throcytes, debris, and leukocytes. The apoptosis analysis
was determined by Annexin V kit (Pharmingen, Benton
Dickinson) and propidium iodide (PI) as previuosly
reported [11]. Flow cytometric analyses were performed
on a FACScalibur flow cytometer (Benton Dickinson).
Each sample was analyzed using 5000 events/sample
acquired in list mode by a Macintosh Quadra 650 mini-
computer (Apple Computer Inc., Cupertino). Data ana-
lysis was performed via three-step procedure using the
Cellquest software (Benton Dickinson). Apoptosis levels
were measured at four radiation doses (0, 2, 4, and 8
Gy) in triplicate. Statistical analyses were performed
using the SPSS Statistical Package (version 15.0 for Win-
dows) as previously reported [11].
Results
Radio-induced apoptosis (RIA) could be defined as the
percentage of total PBLs death induced by the radiation
dose minus the spontaneous cell death (control, 0 Gy).
RIA values increased with radiation dose (0, 1, 2 and 8
Gy) (Table 3), and fitted to a semi logarithmic equation
as follow: RIA = b ln(Gy) + a (Figure 1). b values fol-
lowed a normal distribution (mean 11.02 ± 3.61, range
4.02-19.61, median 11.32) and seems to represent a per-
sonalized marker of radiosensitivity. The adjustment
coefficients (R) were determined and data strongly fitted
to a semi logarithmic mathematical model. Correlation
values at 24 hours were: mean 0.97 ± 0.44, median 0.99,
range 0.76-1. Also, the intraindividual and interindivi-
dual variations were determined in the four healthy
donors and in the 79 patients. Intraindividual variation
for healthy donors was always lower than interindividual
variation for patients (data not shown).
Cutaneous, mucosa, subcutaneous, laryngeal and eso-
phageal toxicities as well as xerostomia were evaluated
according to the RTOG scoring system (Table 2). The
majority of patients did not suffer toxicity or suffered
low grade of toxicity, especially mucosa (96.2%), laryn-
geal (98.7%) and oesophageal damage (91.1%). A Log
Rank analysis was performed to evaluate the relationship
between b and the different normal tissue toxicity reac-
tions observed. Patients were segregated based on the
median distribution of b value (cut-off ± 11.32). b 24
values below the median were related with higher severe
xerostomia toxicity, grade 3 (p = 0.035; Exp(B) 0.224, I.
C.95% (0.060-0.904)) (Table 4). As expected, toxicity
was marginally associated with radiation schedule, that
determines the total dose of radiation received (p =
0.058; Exp(B) 3.950, I.C.95% (0.955-13.88)) (Table 4).
The Kaplan-Meier analysis makes visible the relation
between b radiosensitivity constant and xerostomia
grade 3 (Figure 2). Age at the time of diagnosis (patients
were segregated according to the median age), gender,
tumour localization, RT schedule and other concomitant
treatments including chemotherapy, surgery and
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observed in any case (Table 4).
Discussion
Head and neck cancer is treated mainly by surgery and
radiotherapy. Normal tissue toxicity due to radiotherapy
(RT) limits the efficacy of the treatment. Different pre-
dictive toxicity assays have been developed [8]. Anyhow,
analysis of radiation induced apoptosis (RIA) in periph-
eral blood lymphocytes (PBLs) by flow cytometry seems
to be a useful approach to determine individual variabil-
ity to RT [9]. We reported recently that RIA and late
toxicity were related at different radiation doses and
time points, and data strongly fitted to a semi logarith-
mic mathematical model defined by two constants: a
and b [11]. In the present study we made the same
approach in a set of 79 head and neck cancer patients.
We observed that RIA values increased with radiation
dose (0, 1, 2 and 8 Gy) and fitted to a semi logarithmic
equation confirming our previously reports made in 94
cervix cancer patients. Higher levels of b values were
significantly associated to lower levels of late toxicity.
This finding agree with previous studies [9,14] where
RIA presented higher levels in healthy patients com-
pared with radio-sensitive patients and patients who suf-
fered ataxia-telangiectasia (AT) [15] as well as in
different subpopulations of lymphocytes [12,16]. The
loss of salivary gland function is not life-threatening, but
it can dramatically reduce the quality of life and may
lead to impairment of social activities for long-term sur-
vivors [17]. Permanent mouth dryness can also result in
sticky salvia, dental decay, and nutritional problems
[17]. b value predicted only xerostomia in our study.
This fact could be explained because xerostomia was
Table 1 Characteristics of the patients in study (n = 79)
Cases Percentages
Gender
Male 72 91
Female 79
Cancer site
Oral cavity and Oropharynx 29 36.7
Larynx and Hypopharynx 26 32.9
Nasopharynx and Unknown origin/Multiple 24 30.4
Stage
III 20 25.3
IVA 42 53.2
IVB 17 21.5
Histology
Epidermoid 67 84.8
Others 12 15.2
RT schedule
Conventional 35 44.3
Hyperfractionated 44 55.7
Concomitant treatments
CMT 42 53.2
Surgery 20 25.3
Amifostine 23 29.1
RT: radiotherapy, CMT: chemotherapy
Table 2 Toxicity observed in 79 Head and Neck cancer
patients
Late Toxicity Grade 0 Grade 1 Grade 2 Grade 3
Cutaneous 26 (31.9%) 35 (44.3%) 17 (21.5%) 1 (1.3%)
Mucosa 44 (55.7%) 32 (40.5%) 2 (2.5%) 1 (1.3%)
Subcutaneous 33 (41.8%) 34 (43.0%) 11 (13.9%) 1 (1.3%)
Xerostomia 17 (21.6%) 28 (35.4%) 25 (31.6%) 9 (11.4%)
Larynx 54 (68.3%) 24 (30.4%) 1 (1.3%) 0 (0.0%)
Esophago 54 (68.3%) 18 (22.8%) 3 (3.8%) 4 (5.1%)
Table 3 Data of apoptosis and radio-induced apoptosis
(RIA) of PBLs treated with 0, 1, 2 and 8 Gy of radiation at
24 hours.
Dose (Gy) Apoptosis, 24 h RIA, 24 h
0 39. 88 ± 14.80
1 52.83 ± 13.30 13.00 ± 5.47
2 60.11 ± 11.97 20.15 ± 8.37
8 75.66 ± 10.53 35.78 ± 10.12
Cells were isolated from 79 Head and Neck cancer patients. Mean ± SD was
included. RIA data followed a normal distribution (Kolmogorov-Smirnoff test, p
= NS) and strongly fitted to a semi logarithmic model
RIA: Radio-induced apoptosis
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logarithmic model defined by two constants: a is the origin of the curve in the Y axis and determines the percentage of spontaneous cell
death and b is the slope of the curve and determines the percentage of cell death induced at a determined radiation dose.
Table 4 Relation between xerostomia free survival and different variables (Log Rank test)
Variables Free survival at 60 months (%) Exp(B), CI 95%; p value
Age (years)
< 58 89.7
>58 68.4 0.460 (0.109-1.702); 0.160
Gender
Male 82.0
Female 80.0 1.676 (0.261-10.22); 0.601
Tumour localization
OC + Or
a 73.1
(avs.b) 2.166 (0.306-13.04); 0.524
L+H
b 100
(avs.c) 1.146 (0.281-4.712); 0.845
N + U/M
c 84.4
(bvs.c) 0.960 (0.101-9.101); 0.970
RT schedule
Conventional 88.9
Hyperfractionated 77.6 3.950 (0.955-13.88); 0.058
CMT
Yes 87.2
No 80 0.755 (0.188-2.926); 0.669
Surgery
Yes 94.7
No 76.8 3.910 (0.670-11.16); 0.161
Amifostine
Yes 81.5
No 85.5 0.617 (0.071-3.726); 0.510
b 24
< 11.32 92.9
> 11.32 73.9 0.224 (0.060-0.904); 0.035
OC: oral cavity, Or: oropharynx, L: larynx, H: hypopharynx; N: nasopharynx,
U/M: unknown origin/multiple, RT: radiotherapy, CMT: chemotherapy
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ber of cases (43% of patients suffered grade 2-3 of xer-
ostomia) as other severe toxicity reactions were
infrequent even at higher radiation doses. Xerostomia
was also associated with the total dose of radiation
received. This finding agree with other studies where
doses <26-30 Gy, using intensity-modulated radiother-
apy (IMRT), significantly preserve salivary gland func-
tion [18]. In fact, xerostomia was predicted by b values
at 24 hours. Moreover, in multivariate analysis b 24 was
strongly associated with severe xerostomia with an Exp
(B) of 1.583 (95% confidence interval, 1.075-2.331, p =
0.020). Amifostine is a cytoprotective agent against
radiotherapy. The efficacy of amifostine has been a sub-
ject of clinical studies in different cancer types [19]. It
has been reported that patients with head and neck
squamous cell carcinoma treated with amifostine prior
to RT had lower incidence of chronic xerostomia
[20-22]. We did not observe this cytoprotective effect,
probably due to the small number of patients who
received amifostine (n = 23). Anyhow, amifostine was
only approval for reduction of the incidence of xerosto-
mia in patients undergoing postoperative RT alone for
head and neck cancer. Despite this, the use of this agent
remains limited [19]. PBLs apoptosis, measured as an
integrated value of radio-sensitivity (from 1 to 8 Gy),
seems to has the potential to predict which patients will
be spared late toxicity after radiation therapy. Feasibility
and cost effectiveness of this assay would favour larger
studies to analyze the predictive role of this model,
especially in different lymphocyte subpopulations. Any-
how, constant b, that defines the individual radio-sensi-
tivity and represents the predictive value, need extensive
and prospective studies to be validated.
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